Separase Inhibition Enhances Gefitinib Sensitivity of Lung Cancer via PTBP1/TAK1/RIPK1-Mediated PANoptosis

Abstract

Gefitinib is the most frequently employed anti-lung cancer drug, but its clinical effectiveness is often compromised due to the development of drug resistance. Given that gefitinib failure to long-term inhibition of the growth of lung carcinoma cell lines, which mirrors the resistance observed in clinical patients, new approaches to improve the curative effect of gefitinib should be found. Surprisedly, inhibiting separase with the specific inhibitor Sepin-1 has been found to effectively enhance gefitinib-induced cytotoxic in lung cancer cell by promoting the development of PANoptosis, which includes pyroptosis, apoptosis, and necroptosis. Moreover, in vivo experiments also demonstrated that the combination of Sepin-1 and gefitinib can induce significant regression of lung xenograft tissues. Mechanically, loss of separase plus gefitinib decreases the expression of PTBP1 and TAK1. Overexpression of PTBP1 or TAK1 suppresses this interaction-induced PANoptosis by promoting the inactivation of RIPK1. In addition, clinical data showed that better effective of gefitinib maybe associated with lower separase expression or higher PANoptosis marker expression in patient lung carcinoma tissues. Thus, these findings provide a novel anti-lung cancer strategy and highlight separase as a potential target for overcoming gefitinib resistance in lung cancer treatment.

Keywords

gefitinib / lung cancer / PANoptosis / RIPK1 / separase / TAK1

References

[1] R. L. Siegel, K. D. Miller, N. S. Wagle, and A. Jemal, “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73 (2023): 17-48.

[2] P. T. Harrison, S. Vyse, and P. H. Huang, “Rare Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer,” Seminars in Cancer Biology 61 (2020): 167-179.

[3] X. Lin, R. Ye, Z. Li, et al., “KIAA1429 Promotes Tumorigenesis and Gefitinib Resistance in Lung Adenocarcinoma by Activating the JNK/MAPK Pathway in an M(6)A-Dependent Manner,” Drug Resistance Updates 66 (2023): 100908.

[4] L. Huang and L. Fu, “Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors,” Acta Pharmaceutica Sinica B 5 (2015): 390-401.

[5] D. Westover, J. Zugazagoitia, B. C. Cho, C. M. Lovly, and L. Paz-Ares, “Mechanisms of Acquired Resistance to First- and Second-Generation EGFR Tyrosine Kinase Inhibitors,” Annals of Oncology 29 (2018): i10-i19.

[6] S. G. Wu and J. Y. Shih, “Management of Acquired Resistance to EGFR TKI-Targeted Therapy in Advanced Non-Small Cell Lung Cancer,” Molecular Cancer 17 (2018): 38.

[7] D. M. Granoff, S. J. Holmes, R. B. Belshe, M. T. Osterholm, J. E. McHugh, and E. L. Anderson, “Effect of Carrier Protein Priming on Antibody Responses to Haemophilus influenzae Type b Conjugate Vaccines in Infants,” Jama 272 (1994): 1116-1121.

[8] S. Bedoui, M. J. Herold, and A. Strasser, “Emerging Connectivity of Programmed Cell Death Pathways and Its Physiological Implications,” Nature Reviews Molecular Cell Biology 21 (2020): 678-695.

[9] D. Bertheloot, E. Latz, and B. S. Franklin, “Necroptosis, Pyroptosis and Apoptosis: An Intricate Game of Cell Death,” Cellular & Molecular Immunology 18 (2021): 1106-1121.

[10] S. B. Kovacs and E. A. Miao, “Gasdermins: Effectors of Pyroptosis,” Trends in Cell Biology 27 (2017): 673-684.

[11] M. Fritsch, S. D. Günther, R. Schwarzer, et al., “Caspase-8 Is the Molecular Switch for Apoptosis, Necroptosis and Pyroptosis,” Nature 575 (2019): 683-687.

[12] X. Tong, R. Tang, M. Xiao, et al., “Targeting Cell Death Pathways for Cancer Therapy: Recent Developments in Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis Research,” Journal of Hematology & Oncology 15 (2022): 174.

[13] X. Sun, Y. Yang, X. Meng, J. Li, X. Liu, and H. Liu, “PANoptosis: Mechanisms, Biology, and Role in Disease,” Immunological Reviews 321, no. 1 (2023): 246-262.

[14] A. Pandeya and T. D. Kanneganti, “Therapeutic Potential of PANoptosis: Innate Sensors, Inflammasomes, and RIPKs in PANoptosomes,” Trends in Molecular Medicine 30, no. 1 (2023): 74-88.

[15] R. Schwarzer, H. Jiao, L. Wachsmuth, A. Tresch, and M. Pasparakis, “FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells,” Immunity 52 (2020): 978-993.e976.

[16] R. S. Malireddi, P. Gurung, S. Kesavardhana, et al., “Innate Immune Priming in the Absence of TAK1 Drives RIPK1 Kinase Activity-Independent Pyroptosis, Apoptosis, Necroptosis, and Inflammatory Disease,” Journal of Experimental Medicine 217 (2020): jem/2019164.

[17] S. Hellmuth and O. Stemmann, “Separase-Triggered Apoptosis Enforces Minimal Length of Mitosis,” Nature 580 (2020): 542-547.

[18] N. K. Maier, J. Ma, M. A. Lampson, and I. M. Cheeseman, “Separase Cleaves the Kinetochore Protein Meikin at the Meiosis I/II Transition,” Developmental Cell 56 (2021): 2192-2206.e2198.

[19] N. Zhang and D. Pati, “Biology and Insights Into the Role of Cohesin Protease Separase in Human Malignancies,” Biological Reviews of the Cambridge Philosophical Society 92 (2017): 2070-2083.

[20] N. Zhang, G. Ge, R. Meyer, et al., “Overexpression of Separase Induces Aneuploidy and Mammary Tumorigenesis,” PNAS 105 (2008): 13033-13038.

[21] R. Meyer, V. Fofanov, A. Panigrahi, F. Merchant, N. Zhang, and D. Pati, “Overexpression and Mislocalization of the Chromosomal Segregation Protein Separase in Multiple Human Cancers,” Clinical Cancer Research 15 (2009): 2703-2710.

[22] J. A. Engelman, K. Zejnullahu, T. Mitsudomi, et al., “MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling,” Science 316 (2007): 1039-1043.

[23] H. A. Yu, M. E. Arcila, N. Rekhtman, et al., “Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients With EGFR-Mutant Lung Cancers,” Clinical Cancer Research 19 (2013): 2240-2247.

[24] S. Zhu, T. Zhang, L. Zheng, et al., “Combination Strategies to Maximize the Benefits of Cancer Immunotherapy,” Journal of Hematology & Oncology 14 (2021): 156.

[25] M. Miller and N. Hanna, “Advances in Systemic Therapy for Non-Small Cell Lung Cancer,” Bmj 375 (2021): n2363.

[26] S. Lee, R. Karki, Y. Wang, L. N. Nguyen, R. C. Kalathur, and T. Kanneganti, “AIM2 Forms a Complex With Pyrin and ZBP1 to Drive PANoptosis and Host Defence,” Nature 597 (2021): 415-419.

[27] J. Geng, Y. Ito, L. Shi, et al., “Regulation of RIPK1 Activation by TAK1-Mediated Phosphorylation Dictates Apoptosis and Necroptosis,” Nature Communications 8 (2017): 359.

[28] D. Zhang, L. Han, F. Du, et al., “FGFR1 Induces Acquired Resistance against Gefitinib by Activating AKT/mTOR Pathway in NSCLC,” OncoTargets and Therapy 12 (2019): 9809-9816.

[29] D. Liu, P. Zhang, J. Zhou, et al., “TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation,” Cell Metabolism 31 (2020): 726-740.e728.

[30] B. Shu, Y. Zhou, H. Li, R. Zhang, C. He, and X. Yang, “The METTL3/MALAT1/PTBP1/USP8/TAK1 Axis Promotes Pyroptosis and M1 Polarization of Macrophages and Contributes to Liver Fibrosis,” Cell Death Discovery 7 (2021): 368.

[31] X. CHEN, Y. PAN, S. ZHANG, et al., “Rechallenge With gefitinib Following Severe Drug-induced Hepatotoxicity in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review,” Oncology Letters 7 (2014): 878-880.

[32] R. R. Shah, J. Morganroth, and D. R. Shah, “Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives,” Drug Safety 36 (2013): 491-503.

[33] L. Osmani, F. Askin, E. Gabrielson, and Q. K. Li, “Current WHO Guidelines and the Critical Role of Immunohistochemical Markers in the Subclassification of Non-Small Cell Lung Carcinoma (NSCLC): Moving From Targeted Therapy to Immunotherapy,” Seminars in Cancer Biology 52 (2018): 103-109.

[34] Z. Peng, P. Wang, W. Song, et al., “GSDME Enhances Cisplatin Sensitivity to Regress Non-Small Cell Lung Carcinoma by Mediating Pyroptosis to Trigger Antitumor Immunocyte Infiltration,” Signal Transduction and Targeted Therapy 5 (2020): 159.

[35] Z. Zhang, Y. Zhang, S. Xia, et al., “Gasdermin E Suppresses Tumour Growth by Activating Anti-Tumour Immunity,” Nature 579 (2020): 415-420.

[36] M. Zheng, R. Karki, P. Vogel, and T. D. Kanneganti, “Caspase-6 Is a Key Regulator of Innate Immunity, Inflammasome Activation, and Host Defense,” Cell 181 (2020): 674-687.e613.

[37] M. Zheng and T. D. Kanneganti, “The Regulation of the ZBP1-NLRP3 Inflammasome and Its Implications in Pyroptosis, Apoptosis, and Necroptosis (PANoptosis),” Immunological Reviews 297 (2020): 26-38.

[38] S. Oh, J. Lee, J. Oh, et al., “Integrated NLRP3, AIM2, NLRC4, Pyrin Inflammasome Activation and Assembly Drive PANoptosis,” Cellular & Molecular Immunology 20 (2023): 1513-1526.

[39] R. Karki, B. Sundaram, B. R. Sharma, et al., “ADAR1 Restricts ZBP1-Mediated Immune Response and PANoptosis to Promote Tumorigenesis,” Cell Reports 37 (2021): 109858.

[40] J. E. Chaft, A. Rimner, W. Weder, C. G. Azzoli, M. G. Kris, and T. Cascone, “Evolution of Systemic Therapy for Stages I-III Non-Metastatic Non-Small-Cell Lung Cancer,” Nature Reviews Clinical Oncology 18 (2021): 547-557.

[41] N. Gurvits, E. Löyttyniemi, M. Nykänen, T. Kuopio, P. Kronqvist, and K. Talvinen, “Separase Is a Marker for Prognosis and Mitotic Activity in Breast Cancer,” British Journal of Cancer 117 (2017): 1383-1391.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.